来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

未开盘 11-18 16:08:08

10.700

-0.440

-3.95%

最高11.440	最低10.380	成交量395.47万
今开11.280	昨收11.140	日振幅9.52%
总市值41.74亿	流通市值41.74亿	总股本3.90亿
成交额4,235万	换手率1.01%	流通股本3.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":10.7,"timestamp":1731917288015,"preClose":11.14,"halted":0,"volume":3954672,"delay":0,"floatShares":390100350,"shares":390100350,"eps":-1.8082619,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.44,"latestTime":"11-18 16:08:08","open":11.28,"high":11.44,"low":10.38,"amount":42346954,"amplitude":0.095153,"askPrice":10.72,"askSize":16500,"bidPrice":10.7,"bidSize":28500,"shortable":0,"etf":0,"ttmEps":-0.8929295742930311,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1687968000000,"adjPreClose":11.14,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":0.6458797116539213,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2483899071","title":"来凯医药-B盘中异动 急速上涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483899071","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483899071?lang=zh_cn&edition=full","pubTime":"2024-11-14 11:22","pubTimestamp":1731554542,"startTime":"0","endTime":"0","summary":"2024年11月14日早盘11时22分，来凯医药-B股票出现异动，股价大幅上涨5.10%。截至发稿，该股报11.960港元/股，成交量346.208万股，换手率0.89%，振幅8.61%。来凯医药-B股票所在的生物技术行业中，整体跌幅为1.05%。其相关个股中，晶泰科技、康宁杰瑞制药-B、迈博药业-B涨幅较大，振幅较大的相关个股有晶泰科技、中国抗体-B、康宁杰瑞制药-B，振幅分别为33.13%、16.82%、13.33%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114112222a235db56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114112222a235db56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2483802204","title":"来凯医药-B11月13日主力资金流入507万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483802204","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483802204?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:15","pubTimestamp":1731485757,"startTime":"0","endTime":"0","summary":"11月13日, 来凯医药-B股价涨0.35%，报收11.38元，成交金额5243万元，换手率1.21%，振幅9.70%，量比0.75。来凯医药-B今日主力资金净流入507万元，连续3日净流入，上一交易日主力净流入191万元，今日环比增加165.45%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为80.00%，平均涨幅为10.55%。该股近5个交易日下跌1.22%，主力资金累计净流入1154万元；近20日主力资金累计净流入7643万元，其中净流入天数为16日。该股主力净额占比0.11%，港股市场排名49/2644。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161621a23323d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161621a23323d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2483109242","title":"来凯医药-B盘中异动 股价大跌5.11%报10.760港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483109242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483109242?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:41","pubTimestamp":1731462072,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘09时41分，来凯医药-B股票出现波动，股价急速跳水5.11%。截至发稿，该股报10.760港元/股，成交量42.65万股，换手率0.11%，振幅8.47%。资金方面，该股资金流入111.018万港元，流出262.637万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.85%。其相关个股中，贝康医疗-B、复旦张江、博安生物涨幅较大，振幅较大的相关个股有宜明昂科-B、来凯医药-B、思路迪医药股份，振幅分别为16.11%、8.29%、7.14%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111309411298e423ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111309411298e423ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2482247440","title":"来凯医药-B盘中异动 股价大涨5.23%报11.260港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482247440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482247440?lang=zh_cn&edition=full","pubTime":"2024-11-11 11:56","pubTimestamp":1731297403,"startTime":"0","endTime":"0","summary":"2024年11月11日临近午盘11时56分，来凯医药-B股票出现波动，股价大幅拉升5.23%。截至发稿，该股报11.260港元/股，成交量183.1万股，换手率0.47%，振幅9.16%。资金方面，该股资金流入1064.28万港元，流出587.524万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.11%。其相关个股中，科济药业-B、东曜药业-B、正大企业国际涨幅较大，振幅较大的相关个股有科济药业-B、绿竹生物-B、同源康医药-B，振幅分别为23.28%、22.22%、18.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111115643971a596d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111115643971a596d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2482424057","title":"来凯医药－Ｂ(02105)股价上升5.234%，现价港币$11.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2482424057","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482424057?lang=zh_cn&edition=full","pubTime":"2024-11-11 11:56","pubTimestamp":1731297360,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在上午11:56比前收市价上升5.234%，现股价为港币$11.26。至目前为止，今日最高价为$11.26，而最低价为$10.28。总成交量为182.85万股，总成交金额为港币$1.972千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2411111485/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2481929233","title":"来凯医药-B11月07日主力资金流入60万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2481929233","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481929233?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:17","pubTimestamp":1730967441,"startTime":"0","endTime":"0","summary":"11月07日, 来凯医药-B股价跌4.00%，报收11.04元，成交金额6818万元，换手率1.54%，振幅11.13%，量比0.54。来凯医药-B今日主力资金净流入60万元，连续7日净流入，上一交易日主力净流入748万元，今日环比减少91.98%。该股近5个交易日上涨36.13%，主力资金累计净流入3471万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入6533万元，其中净流入天数为14日。该股主力净额占比0.01%，港股市场排名301/2643。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107161829a21fc2af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107161829a21fc2af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2481621048","title":"来凯医药-B11月06日获主力加仓748万元 环比增加780.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481621048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481621048?lang=zh_cn&edition=full","pubTime":"2024-11-06 16:15","pubTimestamp":1730880956,"startTime":"0","endTime":"0","summary":"11月06日, 来凯医药-B股价涨5.89%，报收11.50元，成交金额1.33亿元，换手率2.95%，振幅13.81%，量比1.22。来凯医药-B今日主力资金净流入748万元，连续6日净流入，上一交易日主力净流入85万元，今日环比增加780.00%。该股近5个交易日上涨32.79%，主力资金累计净流入3449万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入6441万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106161612a21bf34f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106161612a21bf34f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1184616879","title":"异动解读 | 来凯医药-B新药LAE102研发获重大进展 股价大涨逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184616879","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184616879?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:18","pubTimestamp":1730877533,"startTime":"0","endTime":"0","summary":"来凯医药-B于今日盘中大涨10.68%,最新股价重返12港元上方,报12.12港元。市场关注到,公司今日宣布其新药LAE102针对肥胖症的I期临床研究取得重大进展。这项I期临床试验是一项随机、双盲、安慰剂对照研究,旨在评价LAE102注射液的安全性、耐受性及药代动力学,采取静脉输注和皮下注射两种给药方式。据介绍,目前I期临床试验进展顺利,预计2024年底前有望完成单次剂量递增研究。LAE102是公司专注研发的用于治疗肥胖症和相关代谢性疾病的创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02105"],"gpt_icon":0},{"id":"2481644520","title":"港股异动 | 来凯医药-B(02105)再涨超10% LAE102肥胖症I期启动皮下注射研究 年内有望完成单次剂量递增研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2481644520","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481644520?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:11","pubTimestamp":1730877072,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B再涨超10%，截至发稿，涨9.39%，报11.88港元，成交额1.22亿港元。消息面上，来凯医药近期宣布，已经在其I期单剂量递增研究中启动了皮下注射队列。该I期临床试验系一项随机、双盲、安慰剂对照研究，旨在通过静脉输注和皮下注射两种给药方式，评价LAE102注射液的安全性、耐受性及药代动力学。该I期临床试验进展顺利。2024年底前有望完成单次剂量递增研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2481515642","title":"来凯医药－Ｂ(02105)股价显著上升11.602%，现价港币$12.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2481515642","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481515642?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:04","pubTimestamp":1730876640,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在下午03:04比前收市价显著上升11.602%，现股价为港币$12.12。至目前为止，今日最高价为$12.12，而最低价为$10.64。总成交量为1.019千万股，总成交金额为港币$1.177亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2411063445/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2481991696","title":"来凯医药-B盘中异动 早盘股价大涨5.71%报11.480港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481991696","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481991696?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:04","pubTimestamp":1730858652,"startTime":"0","endTime":"0","summary":"2024年11月06日早盘10时04分，来凯医药-B股票出现波动，股价急速拉升5.71%。截至发稿，该股报11.480港元/股，成交量169.1万股，换手率0.43%，振幅7.73%。资金方面，该股资金流入970.226万港元，流出564.106万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.46%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110610041298e40b1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110610041298e40b1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2480373755","title":"来凯医药-B11月04日获主力加仓2168万元 环比增加431.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480373755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480373755?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:16","pubTimestamp":1730708172,"startTime":"0","endTime":"0","summary":"11月04日, 来凯医药-B股价涨26.40%，报收11.54元，成交金额2.17亿元，换手率5.18%，振幅33.73%，量比4.23。来凯医药-B今日主力资金净流入2168万元，连续4日净流入，上一交易日主力净流入408万元，今日环比增加431.37%。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为100.00%，平均涨幅为5.55%。该股近5个交易日上涨28.08%，主力资金累计净流入2441万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入5317万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104161643ab9daed1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104161643ab9daed1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2480270303","title":"港股异动 | 来凯医药-B(02105)尾盘飙升逾30% LAE102肥胖症I期启动皮下注射研究 机构看好公司产品商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2480270303","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480270303?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:39","pubTimestamp":1730705992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B尾盘飙升逾30%，10月中旬至今股价已实现翻倍。截至发稿，涨28.15%，报11.7港元，成交额1.62亿港元。消息面上，来凯医药近日宣布，已经在其I期单剂量递增研究中启动了皮下注射队列。该I期临床试验系一项随机、双盲、安慰剂对照研究，旨在通过静脉输注和皮下注射两种给药方式，评价LAE102注射液的安全性、耐受性及药代动力学。该I期临床试验进展顺利。看好公司产品未来商业化发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2480310488","title":"来凯医药-B盘中异动 股价大涨5.04%报9.590港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480310488","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480310488?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:49","pubTimestamp":1730684988,"startTime":"0","endTime":"0","summary":"2024年11月04日早盘09时49分，来凯医药-B股票出现波动，股价快速拉升5.04%。截至发稿，该股报9.590港元/股，成交量55.95万股，换手率0.14%，振幅6.79%。资金方面，该股资金流入316.457万港元，流出120.232万港元。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.88%。其相关个股中，昭衍新药、华领医药-B、科伦博泰生物-B涨幅较大，振幅较大的相关个股有昭衍新药、方达控股、华领医药-B，振幅分别为22.22%、14.61%、10.40%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104094948971a404c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104094948971a404c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2480343838","title":"来凯医药－Ｂ(02105)股价上升5.148%，现价港币$9.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2480343838","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480343838?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:49","pubTimestamp":1730684940,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在上午09:49比前收市价上升5.148%，现股价为港币$9.6。至目前为止，今日最高价为$9.6，而最低价为$9.0。总成交量为52.6万股，总成交金额为港币$486.473万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241104516/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2480076650","title":"来凯医药-B11月01日获主力加仓408万元 环比增加973.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480076650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480076650?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:17","pubTimestamp":1730449027,"startTime":"0","endTime":"0","summary":"11月01日, 来凯医药-B股价涨12.58%，报收9.13元，成交金额5742万元，换手率1.67%，振幅17.51%，量比1.22。来凯医药-B今日主力资金净流入408万元，连续3日净流入，上一交易日主力净流入38万元，今日环比增加973.68%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为77.78%，平均涨幅为8.29%。该股近5个交易日下跌2.56%，主力资金累计净流出20万元；近20日主力资金累计净流入3149万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101161746a20788e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101161746a20788e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2480044413","title":"来凯医药－Ｂ(02105)股价大幅上升15.043%，现价港币$9.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2480044413","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480044413?lang=zh_cn&edition=full","pubTime":"2024-11-01 11:57","pubTimestamp":1730433420,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在上午11:57比前收市价大幅上升15.043%，现股价为港币$9.33。至目前为止，今日最高价为$9.33，而最低价为$8.03。总成交量为343.85万股，总成交金额为港币$2.981千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2411012381/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2480104138","title":"港股异动 | 来凯医药-B(02105)午前拉升逾14% LAE102肥胖症I期临床研究全速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2480104138","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480104138?lang=zh_cn&edition=full","pubTime":"2024-11-01 11:52","pubTimestamp":1730433134,"startTime":"0","endTime":"0","summary":"来凯医药-B(02105)午前拉升逾14%，截至发稿，涨14.3%，报9.27港元，成交额2771.55万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20241101/20241101115350_57551.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241101/20241101115350_57551.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2479671477","title":"来凯医药-B盘中异动 早盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479671477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479671477?lang=zh_cn&edition=full","pubTime":"2024-10-31 10:45","pubTimestamp":1730342750,"startTime":"0","endTime":"0","summary":"2024年10月31日早盘10时45分，来凯医药-B股票出现异动，股价急速下跌5.10%。截至发稿，该股报8.190港元/股，成交量113.95万股，换手率0.29%，振幅6.84%。资金方面，该股资金流入278.7万港元，流出536.106万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.78%。其相关个股中，华昊中天医药-B、中生北控生物科技、荣昌生物涨幅较大，振幅较大的相关个股有中生北控生物科技、华昊中天医药-B、方达控股，振幅分别为100.00%、37.19%、10.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103110455098e3f95c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103110455098e3f95c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2479241442","title":"来凯医药-B盘中异动 股价大跌5.22%报8.540港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479241442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479241442?lang=zh_cn&edition=full","pubTime":"2024-10-29 14:46","pubTimestamp":1730184412,"startTime":"0","endTime":"0","summary":"2024年10月29日下午盘14时46分，来凯医药-B股票出现波动，股价大幅跳水5.22%。截至发稿，该股报8.540港元/股，成交量389.95万股，换手率1.00%，振幅10.43%。资金方面，该股资金流入1198.96万港元，流出1906.83万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，三叶草生物-B、贝康医疗-B、科济药业-B涨幅较大，振幅较大的相关个股有锦欣生殖、宜明昂科-B、三叶草生物-B，振幅分别为27.98%、22.66%、13.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029144653a1f4552b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029144653a1f4552b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.0564},{"period":"1month","weight":0.3081},{"period":"3month","weight":1.311},{"period":"6month","weight":0.5028},{"period":"1year","weight":-0.5276},{"period":"ytd","weight":-0.4623}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症及肝脏疾病创新疗法的发现、开发及商业化的投资控股公司。该公司主要从事单药疗法及联合疗法的候选药物的研发，专注用于治疗各种癌症及肝纤维化疾病。该公司的主要产品管线包括LAE002及LAE001。LAE002是一种三磷酸腺苷（ATP）竞争性AKT抑制剂，用于治疗卵巢癌、前列腺癌、乳腺癌及PD-1/PD-L1耐药实体瘤。LAE001是雄激素合成抑制剂，可同时抑制细胞色素P450家族17亚族A成员1（CYP17A1）及细胞色素P450家族11亚族B成员2（CYP11B2），用于治疗前列腺癌。该公司主要在中国、美国、欧洲及韩国市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}